May 2014 Pharmaceutical & Biotech Sales Analysis by Country

Transcription

1 May 2014 Pharmaceutical & Biotech Sales Analysis by Country Drugs, Regions

2 EvaluatePharma Foreword W elcome to EvaluatePharma s Product Sales Analysis by Country Report. In this report we have analyzed product sales trends 70 countries for 100 global pharmaceutical companies. The analysis leverages power EvaluatePharma s new Product Sales Analysis by Country service which combes company disclosed product sales and IMS Health s dustry leadg country-level sales. The result is a unique sight to product performance at a region and country level., EU/EEA and Still Domate Sales for Global 100 Products EvaluatePharma fds that established markets (, EU/EEA and ) rema primary source sales for 100 products, accountg for 85% sales In addition, reliance Industry on 100 is revealed, as contribution 100 products to a region s sales tends to converge to 50%. Interestgly, reliance on 100 has decled between 2010 and 2012 US (57% to 55%), EU/EAA (50% to 49%) and (55% to 52%), while BRIC countries reliance has creased from 42% to 46%. A review Oncology sales by region reveals that and EU/EEA Oncology sales ($18.3bn and $14.2bn) were closer than expected, given ir difference overall pharmaceutical market size, between 2010 and Oncology products BRIC countries grew at an impressive 14.3% per year but still lag behd established markets (, EU/EEA and ) terms total sales and account for just 5% global oncology market. EvaluatePharma fds that accounts for 47% global biotechnology products market. The US biotechnology market grew 9.7% per year between 2010 and 2012 with EU/EEA achievg a growth rate 4.8%, agast a backdrop austerity and declg overall EU/EEA sales. Once aga, BRIC countries account for a small part global market at just 3.4%. The report concludes with a case study Rituxan (rituximab), a leadg biotechnology product oncology market, showcasg powerful combation company disclosed product sales and IMS Health dustry leadg country-level sales. Rituxan s performance by country and region is tracked cludg its 63% price drop India after Reditux was launched. Andreas Hadjivasiliou Analyst, EvaluatePharma, EU/EEA and remaed primary source sales for 100 products 2

3 About EvaluatePharma s Product Sales Analysis by Country EvaluatePharma s Product Sales Analysis by Country combes highest-quality strategic sales telligence from Evaluate Ltd. and IMS Health. Evaluate s experts carefully analyze results, tegratg and reconcilg sales, to deliver a high level accuracy and transparency. The Evaluate platform presents a clear, standardized view country-level markets 70 countries and provides rapid reportg functionality. Available as a supplemental module EvaluatePharma service, comparisons sales performance across products, countries, regions, competitors, rapy areas and EphMRA ATC can be conducted. The ultimate value analysis is time savgs allowg more focus on terpretation results to drive busess performance and growth. Highlights clude: Reconciled IMS Health country-level product sales based on IMS Health country audits for 100 companies Up to 100 IMS Health ranked products for each company Reconciled IMS Health private-company coverage IMS Health country sales splits used to calculate and fill country-level gaps Sales results both U.S. dollars and locally reported currency As June 2014 Product Sales Analysis by Country will cover sales, and August 2014 coverage will expand to 200 companies based on IMS Health rankg. For more formation please visit or Contact Us. Reconciled IMS Health country-level products sales from ir country audits for ir ranked 100 companies 3

4 100 Products by Region (, EU/EEA,, BRIC & RoW) 100 Products by Region (, EU/EEA,, BRIC & RoW), EU/EEA and Domate Sales for Global 100 Products EvaluatePharma, EU/EEA and fds that Domate analysis for Sales for 100 Global products dicates 100 Products that established markets (, EU/EEA, ) rema most important EvaluatePharma s terms analysis sales accountg 100 for products 85% sales dicates that established 100 products. markets BRIC (, countries, EU/EEA, despite ) dustry rema attention most important as a growth hotspot, still terms account sales for accountg only 3.5% for sales, 85% on sales. average, BRIC countries, 100 despite products. dustry attention as a growth hotspot, still account for only 3.5% sales, on average, total 100 product sales.. Contribution 100 Products to a Region s Total Sales Converges to to 50% On On reviewg contribution 100 products to to a regions total sales*, we fd that it converges to 50% established markets (, EU/EEA, (, EU/EEA, ). ). BRIC BRIC countries, countries, as y as y develop develop and and ultimately ultimately mature, mature, are are rapidly rapidly movg towards this this 50% 50% contribution level. level. Sales 100 Products Key Regions (,EU/EEA,, BRIC) Rx Sales ($bn) EU/EEA BRIC EU/EEA BRIC Sales 100 Products 2012 by Regions BRIC 3.4% 8.8% EU/EEA 24.6% ROW 11.2% 51.9%, EU/EEA & = 85.2% Sales for 100 Products 2012 by Key Regions 2012 (% Total Brand Sales) Product EU/EEA BRIC ROW 1 Humira 47.2% 37.9% 3.1% 2.5% 9.2% 2 Seretide/Advair 50.2% 29.8% 6.1% 2.4% 11.4% 3 Enbrel 49.8% 32.1% 6.8% 1.0% 10.4% 4 Remicade 47.2% 27.5% 11.7% 4.0% 9.5% 5 Rituxan 46.4% 28.1% 4.3% 6.1% 15.1% 5 Average 48.2% 31.1% 6.4% 3.2% 11.1% 100 Average 51.4% 24.9% 8.9% 3.5% 11.3% Note: The products worldwide were ranked on on total total brand sales. Regional sales sales are are expressed expressed as a as % a % brand brand sales. sales. Products with patents expirg before calendar year year end end were excluded from this analysis. Contribution 100 Products to a Region's Rx Sales ( ) (Based on 100 Companies) Rx Sales ($bn) CAGR Rx Sales ($bn) CAGR Year Year EU/EEA 100 Products % 100 Products % Growth per year 2.2% -5.8% Growth per year 3.0% -9.4% sales ( 100 Co's)* % EU/EEA sales ( 100 Co's)* % Growth per year 3.0% -1.9% Growth per year 4.5% -7.9% 100 as a % 57.3% 56.9% 54.6% 100 as a % 50.1% 49.4% 48.6% BRIC 100 Products % 100 Products % Growth per year 12.9% -5.6% Growth per year 28.4% 14.2% sales ( 100 Co's)* % BRIC sales ( 100 Co's)* % Growth per year 15.4% -1.5% Growth per year 23.5% 8.8% 100 as a % 55.0% 53.8% 51.6% 100 as a % 42.2% 43.9% 46.1% Note: The total sales 100 products were aggregated separately for each year and n calculated as a % Total drug sales (Rx and Generics) Note: The total each sales region. The products products were for aggregated each region separately are ranked for each based year on and EvaluatePharma n calculated as Product a % Sales Total drug Analysis sales by (Rx Country and data. Generics) each region. The 100 products for each region are ranked based on EvaluatePharma Product Sales Analysis by Country data. * * Region/Country totals based on Product Sales Analysis by by Country sales for for Companies, not not total total market market sales. sales. 4

5 Oncology Drug Sales by Region (, EU/EEA,, BRIC & RoW) and EU/EEA Oncology Sales Closer than Expected Between 2010 and 2012 EvaluatePharma fds that Oncology sales US and EU/EEA were closer than expected, given ir difference overall pharmaceutical market size, accountg for 38.5% ($18.3bn) and 30% ($14.2bn) global oncology market. The US Oncology market contued to grow by 1.2% per year between 2010 and 2012, while sales EU/EEA countries decreased durg period by 2.5% per year. Oncology products BRIC countries registered strong growth at 14.3% per year; however despite this double digit growth still only accounted for just 5% global oncology market. Established markets (, EU/EEA & ) domate this rapeutic area accountg for almost 82.5% market. Oncology Sales by Region (%) Contribution to Global EU/EEA $14,390 Oncology Sales & Growth by Region and Contribution to Global Market ( ) Source: EvaluatePharma (April 2014) 60% 50% 40% 30% 20% 10% $18,309 $6,633 Or $5,837 BRIC $2,374 0% -5.0% +0.0% +5.0% +10.0% +15.0% +20.0% % Sales Growth: CAGR Avast Avast and and Alimta Alimta are are only only products products to make to make 5 5 each each region. region. The The 5 oncology 5 oncology products products account account for over for over 50% 50% and EU/ EEA and oncology EU/ EEA sale, oncology sale, 5 contribution 5 contribution drops to 41%. drops In to 41%. Surprisgly top 5 products conta top Leupl, 5 products long sce patent expired conta Leupl, long sce patent expired US & EU/EEA. US & EU/EEA. Note: Sales relate to to Total Total Brand Sales for for Product. Oncology cludes: Alkaloids, Alkylatg agents, Anti-angiogenics, Anti-metabolites, Anti-neoplastic MAbs, Cytotoxic antibiotics, Hormone * rapies, Region/Country Platum totals compounds based on Product and or Sales anti-cancer. Analysis Excludes: by Country Interferons, sales for Immunostimulants 100 Companies, & Immunosuppressants. not total market sales. * Region/Country totals based on Product Sales Analysis by Country sales for 100 Companies, not total market sales. 5

6 Biotech Drug Sales by Region (, EU/EEA,, BRIC &RoW) Biotech Drug Sales by Region (, EU/EEA,, BRIC &RoW) Domates Biotechnology Market as All Regions Grow Strongly EvaluatePharma Domates Biotechnology fds that US Market biotechnology as All Regions market Grow accounted Strongly for 47% global biotechnology market The US biotechnology EvaluatePharma market fds contues that US to biotechnology grow strongly market recordg accounted 9.7% growth for 47% per year between global biotechnology 2010 and market Sales EU/EEA The US displayed biotechnology resilient market contues growth to 4.8%, grow agast strongly a recordg backdrop 9.7% austerity growth and per declg year between overall 2010 EU/EEA and sales. Sales Biotech EU/EEA products displayed BRIC resilient countries growth showed 4.8%, exceptional agast a backdrop levels growth austerity touchg and declg 30% per overall year; EU/EEA however, sales. despite Biotech this products double digit BRIC growth, countries still accounted showed exceptional for just 3.4% levels growth global biotechnology touchg 30% market. per year; Established however, despite markets this (, double EU/EEA digit growth, & ) still contue accounted to for domate just 3.4% this area global accountg biotechnology for almost market. 84% Established global markets market. (, EU/EEA & ) contue to domate this area accountg for almost 84% global market. 60% Biotechnology Sales & Growth by Region and Contribution to Global Market ( ) Source: EvaluatePharma (April 2014) Biotech Sales by Region (%) Contribution to Global 50% $65,483 40% 30% 20% EU/EEA $39,953 Or $18,401 $11,781 10% BRIC $4,774 0% +0.0% +5.0% +10.0% +15.0% +20.0% +25.0% +30.0% +35.0% % Sales Growth: CAGR Note: Bubble = Global Sales Regional Biotech Market WW Sales ($m) CAGR WW Market Share Rank Country/Region ,380 65, % 46.2% 46.6% 2 EU/EEA 36,398 39, % 30.9% 28.5% 3 8,925 11, % 7.6% 8.4% 4 BRIC 2,857 4, % 2.4% 3.4% Sum regions 102, , % 87.2% 86.9% Or 15,051 18, % 12.8% 13.1% Total 117, , % 100% 100% Note: Product Sales Analysis by Country covers 100 companies as ranked by IMS Health 70 countries. 5 Products Selected Biotech Markets 2012 Country/Region Sales ($m) Rank 2012 EU/EEA Humira 4,376 Humira 3,502 Remicade Lantus 3,969 Enbrel 2,558 Avast Enbrel 3,967 Hercept 2,397 Nesp Remicade 3,583 Remicade 2,086 Enbrel Rituxan 3,320 Rituxan 1,999 Synagis 469 Sum 5 19,215 12,541 3,390 Or 46,268 27,412 8,391 Country Total* 65,483 39,953 11,781 % 5 Country Total 29.3% 31.4% 28.8% AbbVie's AbbVie s anti-rheumatism drug Humira leads leads rankgs rankgs two two three three regions regions vestigated. vestigated. Enbrel Enbrel and and Remicade Remicade make make 5 for every 5 region for every vestigated. region vestigated. The 5 products The account 5 products for account almost 30% for almost 30% biotechnology biotechnology sales for each sales region. for each region. Note: Note: Sales Sales relate to Total Brand Brand Sales Sales for for Product. Product. * Region/Country totals based on Product Sales Analysis by Country sales for 100 Companies, not total market sales. * Region/Country totals based on Product Sales Analysis by Country sales for 100 Companies, not total market sales. 6

7 Case Study: Sales by Region/Country Rituxan ( ) Case Study: Sales by Region/Country - Rituxan ( ) Rituxan Grows but Biosimilars a Threat EvaluatePharma Rituxan Grows but fds Biosimilars that global a sales Threat Roche's Rituxan (rituximab) grew 8.2% per year period between 2010 and The importance EvaluatePharma established fds that markets global sales is aga Roche s highlighted Rituxan as (rituximab), EU/EEA grew 8.2% & per year contribute 78.8% period between sales and The corethe markets importance, established EU/EEA and markets is aga grew at highlighted 6.8%, 6.7% as and, 8.7%. EU/EEA Suprisgly, & contribute Russian market 78.8% at 4% sales contribution The to core global markets sales, is, 5th EU/EEA largest country and globally grew for at 6.8%, this product. 6.7% and 8.7%. The Russian market at 4% contribution to global sales, is 5th largest country globally for this product. In 2007 Dr Reddy's launched rituximab, branded Reditux, India which was disclosed to have achieved sales $10m Over In 2007 this Dr period Reddy s launched disclosed a price branded rituximab, Rituxan branded India Reditux, dropped India by approximately which was disclosed 63% from to have $350 achieved per 100mg sales 2006 $10m to around $130 Over this 2010, period followg disclosed availabilty price branded Rituxan product India priced dropped at approximately by approximately $120. In 63% from, $350 per absence 100mg a 2006 to around competitor, $ , average followg manufacturg availabilty price quoted by product CMS priced 2010 at for approximately Rituximab was $120. $594 In per, 100mg. Biosimilars absence are a expected to competitor, enter US average manufacturg price quoted by CMS 2010 for Rituximab was $594 per 100mg. Biosimilars are expected to enter US next few years next few years and it will be terestg to see if decle price seen India will be repeated this market. and it will be terestg to see if decle price seen India will be repeated this market. Rituxan Product Sales Analysis by Region Rituxan Product Sales Analysis by Country 2012 Rx Sales ($m) 3,500 3,000 2,500 2,000 1,500 1, ,910 1,765 1,175 3,078 3,320 2,014 2,011 EU/EEA 1,411 1,514 ROW EU/EEA ROW ROW 35.6% Russia 4.1% 4.3% France 4.4% Germany 5.1% 46.4%, EU/EEA & = 78.8% Rituxan Sales Analysis by Region & Country Drug Sales ($mln) Sales CAGR % Contribution to WW Sales Rank Region/ Country Source ,910 3,078 3,320 Disclosed 6.8% 47.6% 46.4% 2 EU/EAA 1,765 2,014 2,011 Reconciled 6.7% 28.9% 28.1% Germany Reconciled 1.9% 5.8% 5.1% France Reconciled 4.7% 4.7% 4.4% U.K Reconciled 16.3% 2.8% 3.2% Italy Disclosed 2.9% 3.4% 3.1% Spa Reconciled 3.9% 2.8% 2.6% Total EU5 1,190 1,346 1, % 19.5% 18.4% Disclosed 8.7% 4.3% 4.3% 5 Russia Reconciled 23.1% 3.2% 4.1% 6 ROW 1,175 1,411 1,514 Reconciled 13.5% 19.2% 21.2% Worldwide Sales 6,113 6,790 7,155 Disclosed 8.2% Reditux Sales (Dr Reddy's) Disclosed 7.7% Notes Notes about about reconciliation reconciliation analysis: analysis: 1) EvaluatePharma analysts derived reconciled sales Rituxan by multiplyg IMS Health country splits by EvaluatePharma's company disclosed 1) EvaluatePharma worldwide analysts totals. derived reconciled sales Rituxan by multiplyg IMS Health country splits by EvaluatePharma s company disclosed 2) worldwide Rituxan sales totals. for US and were disclosed by Roche. 3) 2) Rituxan sales Rituxan for US sales and for Italy were were disclosed by Roche. by Roche S.p.A. (Italian Subsidiary Account Filg). 4) 3) Italy sales for Rituxan 2012 were sales for calculated Italy were based disclosed on 2011 by Roche Roche S.p.A. S.p.A. (Italian sales Subsidiary adjusted for Account IMS Filg). underlyg growth rate for ) Western Europe 2012 sales were disclosed by Roche and were multiplied by IMS Health Country Splits for Roche defed Western European 4) Italy sales countries for 2012 to were derive calculated country-level based sales on 2011 for Roche region. S.p.A. sales adjusted for IMS underlyg growth rate for ) 5) India Western Reditux Europe sales 2012 and sales prices were (branded disclosed and by Roche and rituximab) were multiplied were disclosed by IMS Health by Dr. Country Reddy's. Splits for Roche defed Western European EvaluatePharma's countries to derive Product country-level Sales sales by Country for region. reconciliations / analysis are fully transparent with service. 6) India Reditux sales and prices (branded and rituximab) were disclosed by Dr. Reddy s. EvaluatePharma s Product Sales by Country reconciliations / analysis are fully transparent with service. 7

8 To download additional copies this report, please visit: Evaluate is trusted source for high-quality life science market telligence and analysis, and exclusive consensus forecasts to Our services are EvaluatePharma, EvaluateClical Trials and EvaluateMedTech. Our editorial arm, EP Vantage, leverages our market telligence and analysis to cut through noise, providg daily opion and sights. Evaluate s services give you sights you need to ask right questions and get right answers. That s telligence you can act on. For more formation visit: IMS Health is a leadg worldwide provider formation, technology and services dedicated to makg healthcare perform better. With a global technology frastructure and unique combation real-world evidence, advanced analytics and proprietary stware platforms, IMS Health connects knowledge across all aspects healthcare to help clients improve patient outcomes and operate more efficiently. Additional formation is available at On Evaluate Headquarters Evaluate Ltd Fashion Street London E1 6PX United Kgdom Tel: +44 (0) Fax: +44 (0) Evaluate North America EvaluatePharma, Inc. 15 Broad Street, Suite 401 Boston, MA Tel: Fax: Evaluate EvaluatePharma KK Tokyo, Tel: +81 (0) Copyright 2014, Evaluate Ltd, All rights reserved. Copyright 2014, Evaluate Ltd, and IMS AG and its affiliates. All rights reserved. Copyright 2014, 2013, 2012, 2011 IMS AG and its affiliates. All rights reserved. Certa trademarks here are owned by IMS Health Incorporated and its affiliates. EVALPSA1